Lidocaine/prilocaine spray (lidocaine and prilocaine spray)

Lidocaine/prilocaine spray (lidocaine and prilocaine spray) is filed as Topical anesthetic. The sections below restate public label fields stored for this profile.

Class
Topical anesthetic
Generic name
lidocaine and prilocaine spray
Route
TOPICAL
Dosage forms
Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. ( 5.1 ) DO NOT INJECT ( 5.2 ) Allergic and anaphylactic reactions can occur ( 5.3 ) Avoid contact with eyes ( 5.4 ) Use with caution in patients with severe hepatic disease ( 5.6 )
Manufacturer
Viona Pharmaceuticals Inc

Approved uses

Oraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing.

How it works

Lidocaine and prilocaine belong to the amide class of local anesthetics. Both lidocaine and prilocaine block sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.

Warnings and precautions

WARNINGS Application of lidocaine and prilocaine cream to larger areas or for longer times than those recommended could result in sufficient absorption of lidocaine and prilocaine resulting in serious adverse effects (see Individualization of Dose ). Patients treated with class III anti-arrhythmic drugs (e.g., amiodarone, bretylium, sotalol, dofetilide) should be under close surveillance and ECG monitoring considered, because cardiac effects may be additive. Studies in laboratory animals (guinea pigs) have shown that lidocaine and prilocaine cream has an ototoxic effect when instilled into the middle ear. In these same studies, animals exposed to lidocaine and prilocaine cream only in the external auditory canal, showed no abnormality. Lidocaine and prilocaine cream should not be used in any clinical situation when its penetration or migration beyond the tympanic membrane into the middle ear is possible. Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias and death. Discontinue lidocaine and prilocaine cream and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion or hyperbaric oxygen.

Contraindications

Oraqix is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to any other component of the product.

Common side effects

N application site reactions were redness (21%); Burning sensation (17%); And edema (10%)

Adverse reactions

Most common adverse reactions (incidence >15%) are application site reactions including pain, soreness, irritation, numbness, ulcerations, vesicles, edema, abscess and/or redness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact DENTSPLY Pharmaceutical at 1-800-989- 8826 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Dosage and administration

Use the included blunt-tipped applicator and the dispenser, which is sold separately, to apply gel to gingival margins and periodontal pockets. ( 2 ) May be reapplied as needed up to a maximum of 5 cartridges per treatment session.( 2 )

Drug interactions

Other local anesthetics or agents structurally related to local anesthetics ( 7.1 ) Drugs That May Cause Methemoglobinemia When Used With ORAQIX ( 7.2 )

Common questions

What is Lidocaine/prilocaine spray approved to treat?

According to its FDA label, Lidocaine/prilocaine spray (lidocaine and prilocaine spray) is approved for: Oraqix is an amide local anesthetic indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing. For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Lidocaine/prilocaine spray?

Lidocaine/prilocaine spray (lidocaine and prilocaine spray) belongs to the Topical anesthetic class of medications.

What form does Lidocaine/prilocaine spray come in?

The FDA label lists Lidocaine/prilocaine spray (lidocaine and prilocaine spray) as: Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. ( 5.1 ) DO NOT INJECT ( 5.2 ) Allergic and anaphylactic reactions can occur ( 5.3 ) Avoid contact with eyes ( 5.4 ) Use with caution in patients with severe hepatic disease ( 5.6 ); topical route. Available strengths and packaging vary by manufacturer.

Does Lidocaine/prilocaine spray have a Boxed Warning?

Our ingest of the FDA label for Lidocaine/prilocaine spray (lidocaine and prilocaine spray) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

Is Lidocaine/prilocaine spray currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Lidocaine/prilocaine spray (lidocaine and prilocaine spray) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Lidocaine/prilocaine spray approved by the FDA?

The FDA record lists the approval date for Lidocaine/prilocaine spray (lidocaine and prilocaine spray) as 2024-12-17.

Who makes Lidocaine/prilocaine spray?

The FDA label lists Viona Pharmaceuticals Inc as a labeler/manufacturer of Lidocaine/prilocaine spray (lidocaine and prilocaine spray). Multiple firms may market generics of the same molecule.

How should Lidocaine/prilocaine spray be stored?

The FDA label states: "Oraqix (lidocaine and prilocaine periodontal gel), 2.5%/2.5%, is supplied in dental cartridges that provide 1.7g gel. Individually blister-packaged cartridges of Oraqix are distributed in a carton of 20 (NDC 66312-110-20…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…